A Randomised Trial Comparing Two Doses of the New Selective Aromatase Inhibitor Anastrozole (Arimidex) With Megestrol Acetate in Postmenopausal Patients With Advanced Breast Cancer

Author： Berry J.   Sahlberg P.   ARIMIDEX Study Group   Jonat W.   Howell A.   Blomqvist C.   Eiermann W.   Winblad G.   Tyrrell C.   Mauriac L.   Roche H.   Lundgren S.   Hellmund R.   Azab M.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.32, Iss.3, 1996-03, pp. : 404-412

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Double-blind, Randomised, Multicentre Endocrine Trial Comparing Two Letrozole Doses, in Postmenopausal Breast Cancer Patients

By Bajetta E.   Zilembo N.   Dowsett M.   Guillevin L.   Di Leo A.   Celio L.   Martinetti A.   Marchiano A.   Pozzi P.   Stani S.   Bichisao E.  

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 208-213

Elsevier

Access to resources Recommend Favorite

Formestane Versus Megestrol Acetate in Postmenopausal Breast Cancer Patients After Failure of Tamoxifen: a Phase III Prospective Randomised Cross Over Trial of Second-line Hormonal Treatment (SAKK 2090)

By Swiss Group for Clinical Cancer Research SAKK   Thurlimann B.   Castiglione M.   Hsu-Schmitz S.F.   Cavalli F.   Bonnefoi H.   Fey M.F.   Morant R.   Lohnert T.   Goldhirsch A.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1017-1024

Elsevier

Access to resources Recommend Favorite

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite

Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial

By Westman G.   Bergman B.   Albertsson M.   Kadar L.   Gustavsson G.   Thaning L.   Andersson M.   Straumits A.   Jeppson B.   Linden   Ewers S.-B.   Andersson H.   Mercke C.   Hafstrom   Birck O.   Orgum P.  

European Journal of Cancer, Vol. 35, Iss. 4, 1999-04 ,pp. : 586-595

Elsevier

Access to resources Recommend Favorite